Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07126782) titled 'The Efficacy and Safety Assessment of Allogeneic ?d T Cells in Patients With MRD-positive AML After Allo-HSCT' on Aug. 11.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Condition:
AML (Acute Myelogenous Leukemia)
AML
Intervention:
Biological: Ex-vivo expanded allogeneic ?d T cells
Recruitment Status: Recruiting
Phase: Early Phase 1
Date of First Enrollment: July 20, 2025
Target Sample Size: 10
Countries of Recruitment:...